Solutions for
Difficult-to-Treat Cancers

FLAG Therapeutics is a near-term clinical stage company focused on developing new small molecule therapeutics for difficult-to-treat cancers. FLAG-003, the company’s lead candidate for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG - a rare and fatal pediatric cancer) and glioblastoma multiform (GBM), is on-track to enter Phase 1 clinical development in early 2026 in children with DIPG.

3 Drug Discovery Platforms
3 Drug Discovery Platforms
FLAG-003 for DIPG + GBM
FLAG-003 for DIPG + GBM
Investors
Investors

Recent News / Events

April 23, 2026

FLAG Therapeutics Secures Over $500,000 in Equity and Impact Funding from Venture and Mission-Driven Investors, Including Springhood Ventures, Kids Beating Cancer, The Musella Foundation, the AYJ Fund, Tough2gether Foundation and DDRFA

October 31, 2025

May is Brain Tumor Awareness Month (May 17 is DIPG Awareness Day)

FLAG Therapeutics presents a poster entitled “Formulation of FLAG-003 Tablets to Support Phase I/II Clinical Testing in Children with DIPG” at the 2026 AACR Brain Cancer Conference

July 16, 2024

21st International Symposium on Pediatric Neuro-Oncology
Poster DIPG68: FLAG-003, A NOVEL, DUAL-ACTION THERAPEUTIC, DEMONSTRATES IN-VITRO ACTIVITYAGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

July 1, 2024

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Click here to view related abstract and poster